Amicus Therapeutics to Present at Cowen and Company 33rd Annual Health Care
CRANBURY, N.J., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief
Executive Officer, will present a corporate overview during the Cowen and
Company 33^rd Annual Health Care Conference in Boston, MA on Monday, March 4,
2013 at 4:50 p.m. ET. A live webcast of the presentation can be accessed
through the Investors section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
small molecule drugs called pharmacological chaperones, a novel,
first-in-class approach to treating a broad range of human genetic diseases.
Amicus' late-stage programs for lysosomal storage disorders include migalastat
HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered
with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220
co-administered with ERT in Phase 2 for Pompe disease.
CONTACT: Amicus Therapeutics
Press spacebar to pause and continue. Press esc to stop.